Stockscreener 앱 받기
60.23
3.10%
1.81
시간 외 거래:
60.34
0.11
+0.18%
전일 마감가:
$58.42
열려 있는:
$58.5
하루 거래량:
5.45M
Relative Volume:
0.86
시가총액:
$23.49B
수익:
$4.30B
순이익/손실:
$571.50M
주가수익비율:
42.16
EPS:
1.4285
순현금흐름:
$570.80M
1주 성능:
+3.74%
1개월 성능:
-13.65%
6개월 성능:
-29.05%
1년 성능:
-19.11%
1일 변동 폭
$58.35
$61.15
1주일 범위
$57.20
$61.15
52주 변동 폭
$54.11
$93.25
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
DXCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
60.23 | 22.78B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
DXCM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (DXCM) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit - PR Newswire
Bank Julius Baer & Co. Ltd Zurich Sells 8,697 Shares of DexCom, Inc. $DXCM - Defense World
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo! Finance Canada
Top 2 Healthcare Stocks Every New Investor Should Know - The Motley Fool
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsDXCM - MarketScreener
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
DCXM DEADLINE ALERT: DexCom, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit - GlobeNewswire
Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device - Yahoo Finance Singapore
Levi & Korsinsky Notifies Shareholders of DexCom, Inc. (DXCM) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire
Dexcom Smart Basal Receives FDA Clearance for Personalized Basal Insulin Dosing - Pharmacy Times
DXCM Deadline Alert: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Dexcom to Release G7 15 Day CGM Next Month - Medical Product Outsourcing
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States - GuruFocus
Dexcom G7 15 day continuous glucose monitoring system to launch on Dec. 1 in the United States - MarketScreener
Dexcom G7 15 Day Continuous Glucose Monitoring System To Launch On Dec. 1 In The United States - TradingView
The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - PR Newswire
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal - Zacks Investment Research
Is DexCom Inc. (DC4) stock cheap by valuation metricsQuarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
FDA clearances: Dexcom, GE HealthCare, Zimmer Biomet, BrainsWay - Modern Healthcare News
DexCom, Inc. $DXCM Shares Acquired by Artisan Partners Limited Partnership - Defense World
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - MarketScreener
Will DexCom Inc. (DC4) stock profit from AI boomWeekly Investment Recap & Technical Analysis for Trade Confirmation - newser.com
Can DexCom Inc. (DC4) stock sustain revenue momentumOil Prices & Long-Term Growth Stock Strategies - newser.com
Bragar Eagel & Squire, P.C. Urges Stockholders of DexCom, - GlobeNewswire
FDA clears Dexcom Smart Basal for insulin optimization - BioWorld MedTech
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming ... - Bluefield Daily Telegraph
The Gross Law Firm Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – DXCM - GlobeNewswire
Dexcom Smart Basal wins FDA Clearance for Type 2 diabetes insulin support - Medical Economics
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
FDA OKs Dexcom’s Insulin Dosing Optimizer for Type 2 Diabetes - Medical Product Outsourcing
DexCom Receives US FDA Approval for Insulin Dosing Optimizer - MarketScreener
Will DexCom Inc. (DC4) stock keep high P E multiplesQuarterly Portfolio Report & Real-Time Market Sentiment Reports - newser.com
DexCom (DXCM) Gains FDA Approval for Smart Basal Insulin Dosing Optimizer - GuruFocus
Dexcom Smart Basal Receives FDA Clearance Becoming the First and - GuruFocus
Dexcom receives FDA clearance for first CGM-integrated basal insulin optimizer By Investing.com - Investing.com South Africa
Dexcom wins FDA nod for smart CGM-integrated basal dosing for type 2 diabetes - MassDevice
Dexcom smart basal receives FDA clearance becoming the first and only CGM-integrated basal insulin dosing optimizer for type 2 diabetes - MarketScreener
Dexcom receives FDA clearance for first CGM-integrated basal insulin optimizer - Investing.com Australia
Dexcom Smart Basal Receives FDA Clearance Becoming the First and Only CGM-integrated Basal Insulin Dosing Optimizer for Type 2 Diabetes - DexCom Investor Relations
Is DexCom Inc. stock a bargain at current levelsJuly 2025 Market Mood & Proven Capital Preservation Methods - newser.com
DexCom Inc. stock outlook for YEAREarnings Recap Report & Fast Entry Momentum Alerts - newser.com
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - NewMediaWire
Investors SueWallSt as DexCom, Inc. Faces Securities Fraud Allegations - Nasdaq
Alberta Investment Management Corp Has $450,000 Position in DexCom, Inc. $DXCM - Defense World
DexCom (DXCM) eyes deeper correction toward $44.11–$20.95 zone - FXStreet
Dexcom Wrongful Death Lawsuit Alleges Continuous Glucose Monitor Failed - AboutLawsuits.com
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Morningstar
Join Class Action to Recover Losses from DexCom, Inc. (DXCM)Contact Levi & Korsinsky Before December 26, 2025 - ACCESS Newswire
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.84%
자본화:
|
볼륨(24시간):